Becton, Dickinson and Company $BDX Stock Acquired by Chemistry Wealth Management LLC

Chemistry Wealth Management LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,612 shares of the medical instruments supplier’s stock after purchasing an additional 2,769 shares during the quarter. Chemistry Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $4,227,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Andrews Advisory Associates LLC bought a new stake in Becton, Dickinson and Company during the third quarter valued at about $403,000. Assenagon Asset Management S.A. increased its holdings in Becton, Dickinson and Company by 431.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 41,185 shares of the medical instruments supplier’s stock worth $7,372,000 after acquiring an additional 33,433 shares in the last quarter. Maryland Capital Advisors Inc. raised its stake in Becton, Dickinson and Company by 13,900.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 139 shares during the period. State of Alaska Department of Revenue raised its stake in Becton, Dickinson and Company by 10.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 29,913 shares of the medical instruments supplier’s stock worth $5,354,000 after acquiring an additional 2,915 shares during the period. Finally, Turtle Creek Wealth Advisors LLC lifted its holdings in Becton, Dickinson and Company by 248.1% during the third quarter. Turtle Creek Wealth Advisors LLC now owns 10,012 shares of the medical instruments supplier’s stock valued at $1,792,000 after purchasing an additional 7,136 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,906 shares of company stock valued at $1,265,855 over the last 90 days. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Trading Down 1.3%

Becton, Dickinson and Company stock opened at $191.34 on Friday. The stock has a market cap of $52.72 billion, a P/E ratio of 14.90, a PEG ratio of 13.06 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $195.99. The firm’s 50 day moving average price is $184.03 and its 200-day moving average price is $163.70.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were paid a dividend of $1.05 per share. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Barclays assumed coverage on shares of Becton, Dickinson and Company in a research note on Wednesday, October 7th. They set an “underweight” rating and a $165.00 target price on the stock. TD Cowen upped their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Royal Bank Of Canada increased their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.